PTH and chronic kidney disease: Indeed, in hemodialysis patients, the COSMOS study, a large European prospective study with a 3 year follow up on the clinical handling of more than 6,000 CKD-5D patients, has provided an optimal range of serum PTH that associates with the lowest relative risk of mortality (48).